Tichý Michal, Knopfová Lucia, Jarkovský Jiří, Vlček Petr, Katolická Jana, Čapov Ivan, Hermanová Markéta, Šmarda Jan, Beneš Petr
First Department of Pathological Anatomy, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
J Cancer. 2019 Feb 23;10(6):1393-1397. doi: 10.7150/jca.29530. eCollection 2019.
Colorectal cancer (CRC) represents a serious challenge for oncologists due to high incidence and large heterogeneity. Prognostic factors are needed to stratify patients according to risk of disease progression. In this study, we report that high expression of c-Myb protein, determined by immunohistochemistry (IHC), associates with better overall and disease-free survival (OS, DFS) in a cohort of 103 patients. Although has been previously considered to act as oncogene in CRC, our further analysis of datasets deposited in PrognoScan and SurvExpress databases confirmed that high expression largely associates with good prognosis in CRC. As therapies targeting c-Myb have been developed and tested in preclinical studies, we believe that further studies are needed for detailed understanding of c-Myb function in CRC, before the c-Myb-targeted therapy enters clinical trials.
由于高发病率和巨大的异质性，结直肠癌（CRC）对肿瘤学家来说是一项严峻挑战。需要根据疾病进展风险对患者进行分层的预后因素。在本研究中，我们报告通过免疫组织化学（IHC）测定的c-Myb蛋白高表达与103例患者队列中更好的总生存期和无病生存期（OS，DFS）相关。尽管c-Myb先前被认为在结直肠癌中起癌基因作用，但我们对PrognoScan和SurvExpress数据库中存储的数据集进行的进一步分析证实，c-Myb高表达在很大程度上与结直肠癌的良好预后相关。由于针对c-Myb的疗法已在临床前研究中开发和测试，我们认为在c-Myb靶向疗法进入临床试验之前，需要进一步研究以详细了解c-Myb在结直肠癌中的功能。
